

## Weekly New Drug Approvals

May. 20th 2024

### Pegulicianine


FDA Approval Date: May 16th, 2024

Brand name: Imdelltra

Indication: Extensive stage Small Cell Lung Cancer

Mechanism: CD3 stimulants/DLL3 inhibitors

Company: Amgen



Imdelltra (tarlatamab-dlle) is a first-in-class, bispecific delta-like ligand 3 (DLL3)-directed CD3 T cell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

- Imdelltra received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- Imdelltra is a targeted therapy that brings a patient's own T cells in close proximity to SCLC cells by binding both CD3 on T cells and DLL3 on SCLC cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell.